Compare XBIO & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIO | VNRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.5M |
| IPO Year | 2011 | 2012 |
| Metric | XBIO | VNRX |
|---|---|---|
| Price | $4.33 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 33.7K | ★ 9.7M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.52 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,976,411.00 | $1,727,384.00 |
| Revenue This Year | $2.81 | $355.66 |
| Revenue Next Year | N/A | $849.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.04 | ★ 40.04 |
| 52 Week Low | $1.90 | $0.13 |
| 52 Week High | $13.93 | $3.26 |
| Indicator | XBIO | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 28.70 |
| Support Level | $2.61 | $0.30 |
| Resistance Level | $4.90 | $0.39 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 31.72 | 1.04 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.